The 2022 Tandem Meetings | The impact of omidubicel on access to allogeneic transplantation

Name: The impact of omidubicel on access to allogeneic transplantation
Uploaded: 2022-04-24T00:00:00Z
Duration: 3 min 38 s

Usama Gergis • 24 Apr 2022

The 2022 Tandem Meetings

General Omidubicel

Usama Gergis, MD, MBA, Thomas Jefferson University, Philadelphia, PA, comments on the findings of a hypothetical model investigating the impact of omidubicel on access to allogeneic hematopoietic stem cell transplantation (alloHSCT) in patients with high-risk hematological malignancies who lack match related donors. The model showed that omidubicel led to a significant increase in access to allogeneic transplantation, especially in ethnic minorities. In addition, an ongoing Phase III trial demonstrated that omidubicel use led to faster engraftment and a reduction in fungal and viral infections. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.